Articles > Popular publications > PR Newswire press releases > October-December 2009 > Monday, November 2

Article: YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009.

Article from:
PR Newswire
Article date:
November 2, 2009
Copyright

- Follow-On Results from a Randomized Phase IIb Head & Neck Trial Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated Toxicities -

MISSISSAUGA, ON, Nov. 2 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its EGFR-targeting antibody, nimotuzumab. The "BEST" trial was a randomized four-arm ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: YM BIOSCIENCES INC. - YM BIOSCIENCES ...
PR Newswire UK Disclose;  September 17, 2009 ;     700+ words ...YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR ... reported that nimotuzumab has been approved ... in Mexico. YM BioSciences also announced ... and CEO of YM BioSciences. "As part ... strategy for nimotuzumab, we were also ...

Article: YM BioSciences announces preclinical data ...
PR Newswire;  July 9, 2007 ;     700+ words ... ... is the licensee for nimotuzumab in Japan. In addition, YM BioSciences announced that a paper on the structure of nimotuzumab entitled 'Modeling ... Chairman and CEO of YM BioSciences. About nimotuzumab Nimotuzumab is a humanized ...

Article: YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED ...
PR Newswire;  September 17, 2009 ;     700+ words ... ... reported that nimotuzumab has been approved ... marketing in Mexico. YM BioSciences also announced ... Chairman and CEO of YM BioSciences. "As part of ... registration strategy for nimotuzumab, we were also ... metastases trial YM BioSciences recently enrolled ... trial ...

Article: YM BioSciences Reports Successful Regulatory ...
M2 Presswire;  May 24, 2007 ;     700+ words ... ... Catalyst Reporting: YM BioSciences Reports Successful ... Regulatory Reviews of Nimotuzumab Manufacturing ... Chairman and CEO of YM BioSciences. About Nimotuzumab Nimotuzumab is ... treated with nimotuzumab. About YM BioSciences YM BioSciences ...

Article: YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB ...
PR Newswire;  December 20, 2007 ;     700+ words ... ... evidence to advance nimotuzumab's further development ... Chairman and CEO of YM BioSciences. "Preliminary ... Company. About YM BioSciences YM BioSciences Inc. is an oncology ... stage products: nimotuzumab, a humanized monoclonal ...

Article: YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ...
PR Newswire;  August 21, 2007 ;     700+ words ... ... comprehensive global nimotuzumab development effort ... Chairman and CEO of YM BioSciences. "The proposed ... clinical trials. About YM BioSciences YM BioSciences Inc. is an oncology ... stage products: nimotuzumab, a humanized monoclonal ...

Article: YM BIOSCIENCES INC. - YM BioSciences ...
PR Newswire UK Disclose;  June 8, 2007 ;     700+ words ... ... Business Editors: YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Children with ... patients treated with nimotuzumab. YM BioSciences has previously announced ... initiate a trial with nimotuzumab in colorectal cancer ...

Article: YM BioSciences reports anti-EGFr drug ...
PR Newswire;  July 20, 2006 ;     700+ words ... ... generated in India as nimotuzumab is commercialized ... Chairman and CEO of YM BioSciences. "YM has been ... gain approval for nimotuzumab no cases were ... tesmilifene, YM BioSciences is developing nimotuzumab, an anti-EGFr ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives